B C Foster

Summary

Affiliation: Health Canada
Country: Canada

Publications

  1. ncbi Natural health products and drug disposition
    Brian C Foster
    Therapeutic Products Directorate, Health Canada, Holland Cross 3102C3, Ottawa, Ontario, Canada, K1A 1B6
    Annu Rev Pharmacol Toxicol 45:203-26. 2005
  2. ncbi Comparative study of hop-containing products on human cytochrome p450-mediated metabolism
    Brian C Foster
    Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, Ontario, Canada
    J Agric Food Chem 57:5100-5. 2009
  3. ncbi An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic
    B C Foster
    Office of Science, Therapeutic Products Directorate, Health Canada, Ottawa, Ontario, Canada
    J Pharm Pharm Sci 4:176-84. 2001
  4. ncbi Effect of several Chinese natural health products of human cytochrome P450 metabolism
    Brian C Foster
    Office of Science, Therapeutic Products Directorate, Health Canada, Ottawa, Ontario, Canada Centre for Research in Biopharmaceuticals, University of Ottawa, Ontario, K1A 1B6 Canada
    J Pharm Pharm Sci 5:185-9. 2002
  5. ncbi In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products
    B C Foster
    Office of Science, Therapeutic Products Directorate, Health Canada, Ottawa, Ontario, Canada
    Phytomedicine 10:334-42. 2003
  6. ncbi Foresight scanning: future directions of clinical and pharmaceutical research
    Brian C Foster
    Therapeutic Products Directorate, Health Canada, Ottawa, Ontario, Canada
    J Pharm Pharm Sci 11:108s-22s. 2008
  7. ncbi Therapeutic product disposition in at-risk populations
    Brian C Foster
    Therapeutic Products Directorate, Health Canada, Ottawa, ON, Canada
    Radiat Prot Dosimetry 134:184-90. 2009
  8. ncbi In vitro activity of uva-ursi against cytochrome P450 isoenzymes and P-glycoprotein
    B Chauhan
    Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
    Can J Physiol Pharmacol 85:1099-107. 2007
  9. ncbi CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population
    M Jurima-Romet
    Bureau of Drug Research, Health Canada, Banting Research Centre 2201C, Tunney s Pasture, Ottawa, Ontario, Canada
    Pharmacogenetics 6:329-39. 1996
  10. ncbi Phytochemical and biological analysis of skullcap (Scutellaria lateriflora L.): a medicinal plant with anxiolytic properties
    R Awad
    Ottawa-Carleton Institute of Biology, University of Ottawa, Ottawa, Canada
    Phytomedicine 10:640-9. 2003

Collaborators

Detail Information

Publications22

  1. ncbi Natural health products and drug disposition
    Brian C Foster
    Therapeutic Products Directorate, Health Canada, Holland Cross 3102C3, Ottawa, Ontario, Canada, K1A 1B6
    Annu Rev Pharmacol Toxicol 45:203-26. 2005
    ..Clinical trials should be relevant to the user population and take into account the confounding factors that may influence the interpretation of the findings...
  2. ncbi Comparative study of hop-containing products on human cytochrome p450-mediated metabolism
    Brian C Foster
    Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, Ontario, Canada
    J Agric Food Chem 57:5100-5. 2009
    ..37, suggesting that these components can account for some of the variation in inhibition of CYP metabolism...
  3. ncbi An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic
    B C Foster
    Office of Science, Therapeutic Products Directorate, Health Canada, Ottawa, Ontario, Canada
    J Pharm Pharm Sci 4:176-84. 2001
    ....
  4. ncbi Effect of several Chinese natural health products of human cytochrome P450 metabolism
    Brian C Foster
    Office of Science, Therapeutic Products Directorate, Health Canada, Ottawa, Ontario, Canada Centre for Research in Biopharmaceuticals, University of Ottawa, Ontario, K1A 1B6 Canada
    J Pharm Pharm Sci 5:185-9. 2002
    ..A preliminary study was undertaken with 12 products using a human cytochrome P450 (CYP450) isozyme assay to determine if these products could affect human drug metabolism...
  5. ncbi In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products
    B C Foster
    Office of Science, Therapeutic Products Directorate, Health Canada, Ottawa, Ontario, Canada
    Phytomedicine 10:334-42. 2003
    ..Assessment of the in vitro CYP inhibition potential for these natural products has important implications for predicting the likelihood of natural product-drug interactions if these products are taken concomitantly...
  6. ncbi Foresight scanning: future directions of clinical and pharmaceutical research
    Brian C Foster
    Therapeutic Products Directorate, Health Canada, Ottawa, Ontario, Canada
    J Pharm Pharm Sci 11:108s-22s. 2008
    ..0...
  7. ncbi Therapeutic product disposition in at-risk populations
    Brian C Foster
    Therapeutic Products Directorate, Health Canada, Ottawa, ON, Canada
    Radiat Prot Dosimetry 134:184-90. 2009
    ..The at-risk populations for a serious adverse event are dependent then on the CBRNE event, their physical and cognitive states and the inter-individual intrinsic and extrinsic factors that affect TP disposition...
  8. ncbi In vitro activity of uva-ursi against cytochrome P450 isoenzymes and P-glycoprotein
    B Chauhan
    Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
    Can J Physiol Pharmacol 85:1099-107. 2007
    ..Further studies are warranted against a wider range of cytochrome P450 isozymes and to determine whether these effects are clinically significant...
  9. ncbi CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population
    M Jurima-Romet
    Bureau of Drug Research, Health Canada, Banting Research Centre 2201C, Tunney s Pasture, Ottawa, Ontario, Canada
    Pharmacogenetics 6:329-39. 1996
    ..07-0.17). CYP2C19m2 was not detected in this population. Thus, the Canadian Inuit resemble Caucasian rather than Asian populations in both the incidence of PM phenotype and the molecular basis of the polymorphism...
  10. ncbi Phytochemical and biological analysis of skullcap (Scutellaria lateriflora L.): a medicinal plant with anxiolytic properties
    R Awad
    Ottawa-Carleton Institute of Biology, University of Ottawa, Ottawa, Canada
    Phytomedicine 10:640-9. 2003
    ..These compounds may play a role in anxiolytic activity since baicalin and baicalein are known to bind to the benzodiazepine site of the GABAA receptor and since GABA is the main inhibitory neurotransmitter...
  11. ncbi The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir
    C J L la Porte
    Division of Infectious Diseases, The Ottawa Health Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada
    Clin Pharmacol Ther 82:389-95. 2007
    ..In conclusion, ABCB1 polymorphism has no pronounced effect on saquinavir exposure...
  12. ncbi The effect of natural health products and traditional medicines on the activity of human hepatic microsomal-mediated metabolism of oseltamivir
    Rui Liu
    Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada
    J Pharm Pharm Sci 13:43-55. 2010
    ..Oseltamivir is a prodrug that requires metabolic activation but there is little information on whether natural health products interact to prevent the biotransformation by the carboxylesterase...
  13. ncbi Antiviral drug disposition and natural health products: risk of therapeutic alteration and resistance
    Laura Macdonald
    Therapeutic Products Directorate Health Canada, Holland Cross, Tower B, Ottawa, Ontario, Canada
    Expert Opin Drug Metab Toxicol 5:563-78. 2009
    ..Together, the case reports and limited human clinical studies suggest that the risk for therapeutic alterations and resistance can exist due to changes in pharmacokinetic parameters with concomitant use of these therapeutic products...
  14. ncbi Impact of African herbal medicines on antiretroviral metabolism
    Edward Mills
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    AIDS 19:95-7. 2005
    ..Initiating policies to provide herbal medicines with antiretroviral agents may put patients at risk of treatment failure, viral resistance or drug toxicity...
  15. ncbi Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 cell monolayers by selected commercial-source milk thistle and goldenseal products
    Jason W Budzinski
    Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON K1N6N5, Canada
    Can J Physiol Pharmacol 85:966-78. 2007
    ..Therefore, the modulation of CYP3A4 gene expression can serve as an important marker for the in vitro assessment of NHP-drug interactions...
  16. ncbi Garlic natural health products exhibit variable constituent levels and antimicrobial activity against Neisseria gonorrhoeae, Staphylococcus aureus and Enterococcus faecalis
    Patrick S Ruddock
    Department of Biology, University of Ottawa, P.O. Box 450, Stn A, Ottawa, ON, K1N 6N5, Canada
    Phytother Res 19:327-34. 2005
    ..Thus, many extracts showed discrepancies in both composition, allicin:alliin ratio and antimicrobial activity, raising concerns as to standards of preparation and quality control for these products...
  17. ncbi Effect of high-dose vitamin C on hepatic cytochrome P450 3A4 activity
    Rolf P G van Heeswijk
    Ottawa Hospital and Ottawa Health Research Institute, The University of Ottawa, Ontario, Canada
    Pharmacotherapy 25:1725-8. 2005
    ..To investigate the effect of high-dose vitamin C on cytochrome P450 (CYP) 3A4 activity, and to evaluate possible sex-specific effects on CYP3A4 activity...
  18. ncbi In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4
    Tania Lefebvre
    Office of Science, Therapeutic Products Directorate, Health Canada, Ottawa, Ontario, Canada
    J Pharm Pharm Sci 7:265-73. 2004
    ..Further work is warranted to determine whether valerian root can affect other CYP450 isozymes and how the results of this in vitro investigation can be extrapolated to in vivo situations...
  19. ncbi Actions of ethnobotanically selected Cree anti-diabetic plants on human cytochrome P450 isoforms and flavin-containing monooxygenase 3
    Teresa W Tam
    Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada
    J Ethnopharmacol 126:119-26. 2009
    ..However, the safety of traditional Cree medicines with respect to drug metabolism is unknown...
  20. ncbi Food and therapeutic product interactions - a therapeutic perspective
    Laura Macdonald
    Therapeutic Products Directorate, Health Canada, Holland Cross 3102C3, Ottawa, Ontario, Canada
    J Pharm Pharm Sci 12:367-77. 2009
    ..The later effect is of major concerns among the health practitioners and regulatory officials...
  21. ncbi Community identification of natural health product-drug interactions
    Theresa L Charrois
    CARE Program, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
    Ann Pharmacother 41:1124-9. 2007
    ..Community pharmacists regularly field inquiries regarding NHPs. As such, pharmacists are ideally placed to answer questions about NHP use and interactions with other medications...
  22. ncbi In vitro evaluation of human cytochrome P450 and P-glycoprotein-mediated metabolism of some phytochemicals in extracts and formulations of African potato
    Vipin D P Nair
    Division of Pharmaceutics, Faculty of Pharmacy, Rhodes University, Grahamstown, South Africa
    Phytomedicine 14:498-507. 2007
    ..Appropriate measures are therefore necessary to explore the possibility of such in vitro-in vivo correlations...